secwatch.observer — SEC 8-K summary
======================================

Issuer:     Evofem Biosciences, Inc. (EVFM)
CIK:        0001618835
Form:       8-K
Filed at:   2025-11-26T23:59:59+00:00
Accession:  0001493152-25-025172
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.03, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Evofem stockholders approve reverse stock split (1:500–1,500) and elect four directors
--------------------------------------------------------------------------------

- Stockholders approved reverse stock split of Common Stock at ratio between 1:500 and 1:1,500, with Board discretion to implement by Nov 2026.
- Four directors elected to Class I/II: Kamdar, Rutherford, Rarick, O'Brien; each received over 167M votes for.
- Say-on-pay and 2025 Equity Incentive Plan both approved; BPM LLP ratified as auditor.
- Series E-1 and G-1 preferred stockholders unanimously voted for reverse split.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1618835/000149315225025172/0001493152-25-025172-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1618835/000149315225025172/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-025172

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer